By partnering with NanoPharm company of Aptar Pharma group, Aceso Therapeutics aims to accelerate and secure the development of ACT-101 while reinforcing the program’s unique technological value and inhalation delivery expertise.
By partnering with NanoPharm company of Aptar Pharma group, Aceso Therapeutics aims to accelerate and secure the development of ACT-101 while reinforcing the program’s unique technological value and inhalation delivery expertise.